Mabqi will participate in the Ion Channel-Targeted Drug Development Summit, taking place September 23–24 at Hotel Commonwealth in Boston, USA.
Johanna Marines, Head of Preclinical Development at Mabqi, is invited to give an oral presentation on : Targeting TRPV6 with Bispecific Antibodies to Enable Selective Ion Channel Modulation for Anti-Tumor Activity in Oncology
The presentation will highlight TRPV6 as a promising oncology target, the mechanism of action of a TRPV6-targeting bispecific antibody, and preclinical in vitro and in vivo efficacy data supporting further clinical development.
The summit brings together leaders from biopharma and academia to advance selective and safe ion channel therapeutics through new approaches in electrophysiology, structural biology and translational science.
